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Abstract
Direct antiviral therapy has dramatically changed our possibility to eradicate hepatitis C virus (HCV) 
infection in all stages of chronic liver disease, with sustained virological response rates well above 
90%. HCV eradication should lead to a better prognosis even after cirrhosis has established, including 
a reduced risk of developing hepatocellular carcinoma (HCC). Unfortunately, during the last two 
years different reports have raised the concern about a possible increased risk of developing HCC in 
cirrhotic patients treated with direct antivirals. In this review, we have evaluated the principal published 
data and have reached a few conclusions: (1) direct antiviral therapy does not seem to increase the 
cumulative annual rate of HCC de novo occurrence or recurrence; (2) direct antiviral therapy seems to 
accelerate the development of HCC, soon after the end of treatment, in those patients at higher risk 
of HCC occurrence or recurrence; and (3) preliminary reports seem to indicate that HCC developed 
after direct antiviral therapy has more aggressive features. These findings clearly indicate the need for 
aggressive and close monitoring of cirrhotic patients during and after antiviral treatment, to detect and 
treat HCC at their earliest occurrence.
Keywords: Direct-acting antivirals, hepatocellular carcinoma, liver cirrhosis, risk, hepatitis C
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most frequent form of cancer worldwide, and it holds the 
second place in malignancy-related mortality[1,2]. Incidence and death rates of HCC are steadily rising in 
most parts of the world (about 2%-3% per year).
Chronic hepatitis C is a necro-inflammatory process of the liver, due to hepatitis C virus (HCV) infection, 
that lasts lifelong and progresses to cirrhosis in about 20% of cases[3]. Even if liver cirrhosis per se is not a 
premalignant lesion, it represents a premalignant condition since almost 90% of HCV-related HCC cases 
emerge after cirrhosis becomes established. The annual occurrence rate of HCC has been estimated to 
be around 3% in HCV-related cirrhosis[4,5]. Surgical resection, radiofrequency ablation and transarterial 
chemoembolization  allow effective treatment of single and small HCC in a significant proportion of patients 
with compensated liver disease, but recurrence is common, affecting about 35% of treated patients after 
2 years[6,7].
The aim of this review was to evaluate the effect of antiviral therapy on the de novo occurrence and 
recurrence of HCC in patients with chronic hepatitis C. We searched all available publications regarding 
“hepatitis C”, “HCC”, “antiviral therapy”, “interferon-free”, “DAA”, “occurrence”, “recurrence” and focused 
our review mainly on the data reported in high-quality full-text format.
EFFECT OF INTERFERON-BASED ANTIVIRAL THERAPY ON THE DEVELOPMENT OF HCC
Until 2011, peg-interferon alfa plus ribavirin combination was the only available therapy for chronic hepatitis 
C. This treatment had only 40%-50% probability of curing HCV infection, and the significant side effects 
contraindicated its use in a significant proportion of patients. Despite these limitations, many patients with 
compensated liver cirrhosis had been treated during the last decade, and the effect of treatment on the 
development of HCC has been evaluated. In summary, achieving sustained virological response (SVR) 
was associated with a reduced risk of developing HCC, in comparison with patients who did not obtain 
an SVR after antiviral therapy[8-10]. Despite these positive results, it remains not clear whether SVR was 
independently associated with the reduced risk of developing HCC. In fact, a different explanation could 
be that SVR occurred in those patients with a lower spontaneous probability of developing HCC, without 
altering the cumulative risk of HCC in the entire population of cirrhotic patients. Also, even in patients who 
obtain SVR, a residual annual rate of HCC is still present, as high as 2% in different groups of patients.
THE ADVENT OF DIRECT-ACTING ANTIVIRALS AGAINST HCV
Since 2013, the therapy of hepatitis C has dramatically changed. Direct-acting antivirals (DAA) are new 
oral drugs, with potent antiviral activity against HCV infection, highly efficacious, relatively safe and well 
tolerated, that can be used in all categories of patients with chronic HCV infection, including those with 
more advanced and even complicated liver disease[11]. This has allowed treatment of a huge cohort 
of patients with liver cirrhosis, obtaining the eradication of HCV infection in the vast majority of them. 
Resolution of HCV infection in these patients leads great expectations about the possibility of preventing 
the most serious complications of liver cirrhosis, including the development of HCC. In the following 
paragraphs, we try to summarize the best existing evidence regarding the effects of DAA-induced HCV 
eradication on the development of HCC in patients with compensated liver cirrhosis.
HCC DEVELOPMENT AFTER DAA THERAPY
The story learned from the interferon era teaches us that eradication of HCV infection is not sufficient 
per se to prevent HCC development after cirrhosis has been established. Due to the possibility of treating 
patients with more advanced liver disease, it is not surprising to expect that a few of them may develop 
HCC despite HCV eradication. This topic became immediately hot after the simultaneous publication 
of two papers from Spain and Italy suggesting a possible increased incidence of HCC after successful 
DAA treatment[12,13]. Since those publications, more than 100 papers, letters or communications have 
been published addressing the problem, without conclusive results. Most of the debate derives from the 
heterogeneity of the different studied population, the inclusion and exclusion criteria, the time points used 
to analyse the incidence rates, the length of follow-up, and finally the radiologic methods used for the 
diagnosis of HCC.
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Regardless of these discrepancies, it is possible to review the published results to draw some conclusions, 
but a few statements need to be addressed at first: (1) the concept of incidence; (2) the characteristics 
of the study population; (3) the starting point and the ending point of the observation period; and (4) the 
distribution of events during the follow-up.
Incidence is a measure of the probability of occurrence of a given condition in a population within a 
specified period. The incidence rate is the number of new cases per population at risk in a given time 
period. From this concept derives that to analyse the incidence rate of HCC after DAA therapy it is 
fundamental to define both the exact starting point and the exact ending point of the observation period. 
Only if these time points are comparable, different study results can be compared.
The study population should be at risk of developing the medical condition. Therefore, the risk should be 
comparable among different study groups before performing any comparison. Since in HCV-related liver 
disease HCC occurs almost exclusively in patients with liver cirrhosis, the population at risk should include 
only patients with advanced liver fibrosis (F4 according to the METAVIR classification).
In analysing the incidence rate of HCC after DAA therapy, we must distinguish between analysing the new 
de novo occurrence of HCC and the recurrence of a new HCC in patients with prior history of successfully 
treated HCC. In the former situation, the starting point should be the end of DAA therapy, in the latter, we 
must distinguish between considering as a starting point the time of the previous HCC treatment or the end 
of DAA treatment. In all cases, the ending point should be defined after DAA therapy end, and the interval 
from the starting point must be clearly assessed.
Another important point is the distribution of events (HCC) during the follow-up. It is known that during 
the natural history of liver cirrhosis the development of de novo incident HCC is not clustered around any 
specific time point[12]. Similarly, HCC recurrence is generally not clustered around specific time points, even 
if recurrence rate is higher during the first two years after curative treatment of the neoplastic nodule[6]. For 
this reason, the median interval between DAA therapy and HCC diagnosis needs to be analysed to assess 
the latency period between exposure to DAA therapy and HCC development.
WHAT PUBLISHED STUDIES TELL US
In Table 1, we have summarized the results of the principal studies addressing the de novo occurrence 
and/or recurrence of HCC in HCV-infected patients, with compensated liver cirrhosis, who have been 
treated with DAA therapy. Due to the heterogeneity of the study populations and the different observation 
periods, any formal meta-analysis seems of limited utility to draw any sound conclusion. It seems more 
important to note some common and peculiar aspects of the results.
At first, we must differentiate between the de novo occurrence of new HCC in cirrhotic patients without 
prior history of HCC and recurrence of HCC in patients with previously treated HCC. In studies analysing 
the former group of patients, the observation period after DAA therapy ranged a median of 6 to 14 months, 
indicating a relatively short follow-up. Despite this short observation period, de novo HCC occurred in 
1.5% to 3.9% of patients. If we consider an expected annual rate of 2% to 3% in these subjects, we can 
conclude that HCC occurrence is certainly not reduced after DAA treatment. On the other hand, we have 
not strong elements to assume that the occurrence rate is increased, without a control group. Therefore, 
the argument of the incidence rate of new HCC after DAA therapy remains unsettled without a definite 
conclusion. In any case, a real increased annual incidence rate of HCC does not seem to happen after 
DAA treatment.
More intriguing data come from the studies on the recurrence of HCC after DAA treatment. The analysis 
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of the recurrence rate must take into account the interval since previous HCC treatment, due to the 
higher HCC recurrence rate during the first 2 years after HCC therapy. The interval since previous HCC 
treatment ranged from 11 to 22 months. On the other hand, the post-DAA follow up period ranged from 6 to 
20 months. During this observation period, the recurrence rate was in the range from 16% to 40%. Due 
to the relatively short post-DAA follow-up and the relatively long pre-DAA interval since previous HCC 
treatment, the recurrence HCC rate does not seem negligible at all. Even in this setting, we can conclude 
that DAA treatment does not reduce HCC recurrence. Again, we have not strong elements to assume that 
the recurrence rate is increased, without a control group. Therefore, also the argument of HCC recurrence 
rate after DAA therapy remains unsettled without a definite conclusion.
A striking finding seems to emerge in both settings: the short median latency period between the exposure 
to DAA and the diagnosis of HCC. This latency period was very short both in the HCC occurrence and 
in the HCC recurrence cases: from a minimum of 2.7 months to a maximum of 5.6 months. As stated in 
the methodology of the studies, all patients had no evidence of HCC when starting DAA treatment. Why 
HCC developed after such a short latency period represents an important question. There is no reason to 
explain the clustering of HCC development soon after the end of DAA treatment in the natural history of 
the disease. Different hypotheses have been postulated to support rapid development of HCC after DAA 
therapy. They are mainly based on the possible dysregulation of the anti-tumor response, after the brutal 
decrease of HCV viral load induced by DAA, and/or the perturbation of the immune surveillance, caused 
by a swift clearance of HCV[20,21]. Despite the absence of conclusive biological explanations, these data 
clearly indicate the need for close imaging evaluations to detect early HCC development after DAA therapy 
in cirrhotic patients.
THE CHARACTERISTICS OF HCC DEVELOPED AFTER DAA THERAPY
In addition to the accelerated development of HCC after DAA therapy, additional alarming data have been 
published on the characteristics of the neoplastic nodules. Two preliminary reports suggested that after 
DAA therapy HCC may present aggressive macroscopic patterns[22,23]. This aspect has been recently 
addressed by a full paper published in European Radiology[15]. The authors compared the imaging features 
of HCC nodules developed after DAA therapy to those not occurred after DAA, in the same population. 
Surprisingly, despite being similar in number and size, neoplastic nodules developed after DAA treatment 
showed imaging features of microvascular invasion in the majority of cases. Microvascular invasion is a 
well-known predictor of recurrence and poor overall survival in HCC, and a major risk factor for early HCC 
recurrence after curative treatment. Additional recent data suggest that HCC occurring after interferon-free 
Table 1: Principal studies reporting detailed data on the occurrence and/or recurrence of HCC after DAA therapy 
in patients with liver cirrhosis
References
Prior 
history of 
HCC
No. of 
patients 
Months between 
HCC treatment 
and DAA start 
(median)
Months of follow-up 
since DAA therapy 
(median)
HCC 
cases, 
n  (%)
Months between 
DAA therapy and 
HCC (median)
De novo HCC occurrence
  Conti et al.[14] (2016) No 285 NA 6 9 (3.2) NR
  Renzulli et al.[15] (2017) No 285 NA 14.1 11 (3.9) 2.7
  Kanwal et al.[16] (2017) No 6690 NA 9 172 (2.6) 5.6
  Bielen et al.[17] (2017) No 273 NA 6 4 (1.5) NR
HCC recurrence
  Conti et al.[14] (2016) Yes 59 12.5 6 17 (28.8) NR
  Kolly et al.[18] (2017) Yes 47 21.5 9.6 19 (40.4) NR
  Reig et al.[13] (2016) Yes 58 11.2 5.7 16 (27.6) 3.5
  Renzulli et al.[15] (2017) Yes 59 12.5 14.1 18 (30.5) 2.8
  Bielen et al.[17] (2017) Yes 29 12 6 5 (17.2) NR
  ANRS cohorts[19] (2016) Yes 152 22.8 20.2 24 (15.8) NR
HCC: hepatocellular carcinoma; DAA: direct-acting antiviral; NA: not applicable; NR: not reported 
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treatment show a rapidly growing pattern and moderately differentiated pathologic characteristics[24]. For 
these reasons, HCC developed after DAA treatment seems to have a more aggressive pattern, predictive 
of more severe clinical outcomes. Even if the clinical significance of these findings needs to be confirmed 
in additional prospective studies, these data corroborate the hypothesis of a different biologic pathway in 
the neoplastic process leading to HCC after DAA treatment.
CONCLUSIONS
In this review, we have analysed the published data on the risk of developing HCC after DAA therapy. 
Even if definite conclusions cannot be probably drawn, there is sufficient evidence to summarize the most 
important findings: (1) direct antiviral therapy does not seem to increase the cumulative annual rate of 
HCC de novo occurrence or recurrence; (2) direct antiviral therapy seems to accelerate the development 
of HCC, soon after the end of treatment, in those patients at higher risk of HCC occurrence or recurrence; 
and (3) preliminary reports seem to indicate that HCC developed after direct antiviral therapy has more 
aggressive features. These findings clearly indicate the need for aggressive and close monitoring of 
cirrhotic patients during and after antiviral treatment, to detect and treat HCC at their earliest occurrence.
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